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ADDITIVE EFFECTS OF 
L-ARGININE INFUSION AND 
LEUKOCYTE DEPLETION 
ON RECOVERY AFTER 
HYPOTHERMIC ISCHEMIA IN 
NEONATAL LAMB HEARTS 
Prior experiments on hypothermic schemia/reperfusion have shown that (1) 
leukocytes have an important role in the injury resulting from hypothermic 
ischemia/reperfusion and (2) endothelial dysfunction with reduced release of 
nitric oxide occurs after hypothermic ischemia/reperfusion. L-Arginine is a 
nitric oxide precursor, and the effects of nitric oxide released from endothelial 
cells include vasorelaxation and inhibition of leukocyte adhesion to endothe- 
lium. The potential roles of an interaction between endothelial dysfunction and 
leukocyte-mediated injury were examined in neonatal hearts. Thirty-two 
isolated, blood-perfused neonatal lamb hearts were subjected to 2 hours of 
10 ~ C cardioplegic ischemia. Group L-arginine received a 3 mmol/L dose of 
L-arginine during the first 20 minutes of reperfusion. In group leukocyte 
depletion, leukocytes were depleted (Sepacell filter) from the perfusate before 
reperfusion. In group L-arginine+leukocyte d pletion, leukocytes were de- 
pleted and a 3 mmol/L dose of L-arginine was infused during early reperfusion. 
The control group had no intervention during reperfusion. At 30 minutes of 
reperfusion, left ventricular maximum developed pressure, positive maximum 
and negative maximum first derivative of left ventricular pressure (dP/dt), 
developed pressure at V10 (volume that produces a left ventricular end- 
diastolic pressure of 10 mm Hg at baseline measurement), and dP/dt at V10 
were measured. Coronary blood flow was continuously monitored and oxygen 
consumption was also measured to evaluate the metabolic recovery. In each 
heart, we also tested coronary vascular resistance response to the endothelium- 
dependent vasodilator acetylcholine 10 -7 mol/L and the endothelium-indepen- 
dent vasodilator t initroglycerin 3 • 10- 5 mol/L to assess endothelial function. 
Results are given as  mean percent recovery of baseline values +- standard 
deviation. Group L-arginine+leukocyte depletion showed significantly greater 
recovery of left ventricular function than the other three groups; and groups 
L-arginine and leukocyte depletion also showed better ecovery than the control 
group (positive maximum dP/dt: control group = 68.3% +- 8.8%, group 
L-arginine = 88.8% -- 3.8%, group L-arginine+leukocyte depletion = 100.6% +- 
8.7%, group leukocyte depletion = 79.3% - 8.1%;p < 0.05). Groups L-arginine 
and L-arginine+leukocyte depletion had higher postischemic coronary blood 
flow than other groups (control group = 133.0% - 31.6%, group L-arginine = 
203.2% _ 32.1%, group L-arginine+leukocyte depletion = 222.0% + 30.4%, 
group leukocyte depletion = 156.3% --- 29.0%; p < 0.05). Group 
L-arginine+leukocyte depletion showed higher oxygen consumption than the 
control group (control group = 76.1% - 19.22.1%, group L-arginine = 96.8% 
-+ 17.6%, group L-arginine+leukocyte depletion = 110.1% - 19.2%, group 
leukocyte depletion = 94.4% - 12.9%, p < 0.05). Groups L-arginine, 
L-arginine+leukocyte d pletion, and leukocyte depletion showed greater 
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recovery of the response to acetylcholine than the control group (control group 
= 39.9% -+ 13.9%, group L-arginine = 61.0% -- 14.8%, group L-arginine+ 
leukocyte depletion = 53.5% - 14.1%, group leukocyte depletion = 57.9% -- 
13.3%), but there were no intergroup differences in the response to trinitroglyc- 
erin (control group = 42.4% --15.6%, group L-arginine = 36.4% "4- 15.4%, group 
L-arginine+leukocyte depletion = 37.7% -- 10.2%, and group leukocyte depletion 
= 36.5% __. 11.5%). Conclusion: Reperfusion with leukocyte depletion and 
L-arginine infusion during reperfusion have additive effects on the recovery of 
mechanical and endothelial function in neonatal lamb hearts. These results 
suggest that the beneficial effects of L-arginine involve mechanisms beyond 
leukocyte inhibition, most likely increased endothelial nitric oxide production. 
(J THORAC CARDIOVASC SURG 1995;110:172-9) 
p r ior exper iments from our laborator ies on hypo- 
thermic ischemia/reperfusion have shown that 
(1) leukocytes have an important  role in the injury 
result ing from hypothermic ischemia/reperfusion 1' 2 
and (2) endothel ia l  dysfunction with reduced re- 
lease of  nitr ic oxide (NO) occurs after hypothermic  
ischemia/reperfusion. 3 NO is produced from the 
semiessential  amino acid L-arginine as it is con- 
verted to L-citrulline by NO synthase in endothel ia l  
cells.4, 5 In the vascular system, NO release f rom 
endothel ia l  cells causes vasorelaxation 6' 7 in vessels. 
as well as inhibit ion of leukocyte aggregation. 8 
We found that L-arginine infusion during early 
reperfusion improves functional recovery of neona-  
tal lamb hearts after cold cardioplegic ischemia, 9 
although others have reported that augmentat ion of
NO product ion by L-arginine mcreases post ischemic 
injury.lo, 11 However,  the precise mechanism for the 
beneficial effects of NO in our exper iments remain 
unclear. This study was designed to investigate the 
interact ions between the endothel ial  dysfunction 
and leukocyte-mediated injury by examining the 
effects of L-arginine infusion with or without leuko- 
cyte deplet ion during reperfusion on functional re- 
covery after cold cardioplegic ischemia. 
Materials and methods 
Experimental preparation. An isolated blood-per- 
fused heart model previously described 1' 2. 3, 9 was used 
to study 32 hearts from neonatal lambs (2.3 to 5.9 kg, 2 
to 7 days old). Animals were anesthetized with intra- 
muscular ketamine (40 mg/kg), intubated, and sup- 
ported by a respirator with inhalation of a 1:1 mixture 
of oxygen and nitrous oxide and 0.5% halothane. 
Through a median sternotomy, an arterial cannula with 
a blood pressure monitoring port was inserted into the 
brachiocephalic artery after systemic heparinization 
(2000 units). Coronary perfusion was established with a 
roller pump (Coronary Perfusion Pump, Olson Medical 
Products Inc., Ashland, Mass.) and oxygenator system 
(Bio-2, American Bentley, Irvine, Calif.) before isola- 
tion of the heart, providing no period of ischemia. After 
insertion of the left ventricular (LV) vent into the apex, 
the heart was isolated and placed on the temperature- 
controlled water bath, Both superior and inferior venae 
cavae were ligated and coronary venous return was 
drained with a cannula inserted into the right ventricle 
through the pulmonary artery. A sampling catheter was 
placed in the coronary sinus via the hemiazygos vein for 
coronary venous blood gas analysis. Heparinized fresh 
homologous blood was used as the perfusate, and it was 
oxygenated with a mixture of 20% oxygen, 5% carbon 
dioxide, and.75% nitrogen by use of a bubble oxygen- 
ator. Arterial pH was maintained at 7.4 (corrected to 
perfusate temperature) with sodium bicarbonate. Se- 
rum potassium and ionized calcium concentrations 
were maintained at 4 to 5 mEq/L and 1.0 mEq/L, 
respectively. 
The temperatures of the perfusate, the water bath, 
and the myocardium were monitored with thermal 
probes. The perfusate and water bath were controlled 
at 37~ by a heater-circulator (model 1252-00, Cole- 
Parmer Instrument Co., Chicago, Ill.) except during the 
hypothermic phase, which was produced by circulating 
ice water. Coronary perfusion pressure was maintained 
constant at 60 mm Hg except during the hypothermic 
and reperfusion phases. A pressure transducer contain- 
ing a latex balloon (SPC-350, Millar Instruments, Inc., 
Houston. Tex.) was placed inside the LV through the 
apex to measure the LV function. A Foley balloon 
catheter (10F) was inserted in the left atrium to preven~ 
the LV balloon from herniating into the left atrium and 
to vent blood and air from the LV. 
Measurements. LV function was measured uring lso- 
volumic contraction by inflating the intraventricular bal- 
loon as described previously 1 2. 3. 9 with 0.5 ml increments 
of saline solution until an LV end-diastolic pressure of 20 
mm Hg was reached. LV pressure and its first derivative 
(dP/dt) were recorded at each volume. The recovery of 
systolic function was evaluated by measuring the maxi- 
mum developed pressure, positive maximum LV dP/dt, 
peak developed pressure at a constant balloon volume 
(V10), and peak dP/dt at V10. V10 was defined as the 
balloon volume to produce an end-diastolic pressure of 10 
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Tab le  I. Baseline measurements 
Control 
Group 
L-ARG LD L-ARG+ LD 
DP(max), mm Hg 125 • 14 
DP(V10), mm Hg 118 --- 17 
dP/dt(max), mm Hg/sec 1910 + 311 
dP/dt(V10), mm Hg/sec 1765 --- 352 
-dP/dt(max), mm Hg 1325 • 125 
CBF, ml/100 gin 261 + 43 
MVO2, 10 .4 ml/gm 3.31 --- 0.70 
Heart rate, beats/rain 198 • 19 
CVRR by ACh infusion, % 13.5 + 5.9 
CVRR by TNG infusion, % 14.9 • 2.4 
133 --+ 11 127 -+ 12 123 -+ 10 
129 -+ 11 116 + 21 122 + 15 
2034 + 208 1827 +- 332 1806 -4- 291 
1910 -4- 249 1608 -+ 415 1661 -+ 332 
1432 -+ 145 1266 -+ 228 1266 -+ 125 
248 -+ 34 310 -+ 78 298 -+ 54 
4.16 -+ 0.64 3.66 -+ 0.71 3.47 -+ 0.95 
212 -+ 19 197 -4- 10 194 --+ 11 
14.1 -+ 5.6 14.9 + 5.2 14.7 + 3.8 
15.0 + 4.7 14.4 -4- 2.5 15.9 --+ 4:4 
DP(max), Maximum peak developed pressure; DP(VIO): peak developed pressure at a constant balloon volume (V10), dP/dt(max), maximum ofpeak positive 
LV dP/dt; dP/dt(VlO), LV dP/dt at VI0; VIO, volume to produce an end-diastolic pressure of10 mm Hg during preischemic period; -dP/dt(max), maximum 
of peak negative/LV dP/dt; CBF, coronary blood flow; MV02, myocardial oxygen consumption; CVRR, coronary vascular resistance r sponse; ACh, 
acetylcholine; TNG, trinitroglycerin; 1.-ARG, L-arginine; LD, leukocyte depletion. Data are shown as mean -+ standard eviation. 
mm Hg during preischemic baseline measurement. Neg- 
ative maximum dP/dt was measured before and after isch- 
emia to assess the diastolic functional recovery. Coronary 
blood flow was assessed continuously by an in-line electro- 
magnetic flowmeter (MFV-31001 Nihon Kohden, Tokyo, 
Japan), which was connected to the venous cannula. This 
flow was considered to represent total coronary blood flow. 
Coronary endothelial f mction was assessed by the coronary 
vascular resistance response to acetylcholine infusion as 
described previously)' 2.3. 9 A vasodilator response to acetyl- 
choline is dependent on the release of endothelium-derived 
relaxing factor. Acetylcholine was infused for 30 seconds into 
the side port of the arterial cannula at rates calculated to 
achieve an arterial concentration of 10 -7 mol/L Maximum 
decrease in coronary vascular esistance during the acetyl- 
choline infusion, divided by baseline coronary vascular esis- 
tance, was defined as the coronary vascular esistance re- 
sponse. Trinitroglycerin (3 • 10 -5 tool/L) was infused in the 
same way and the response of the coronary vascular esis- 
tance to infusion of trinitroglycerin was used to assess 
nonendothelium-dependent vasodilator capacity. The pump 
perfusion flow was not changed uring these infusions. Both 
LV function and coronary endothelial function Were mea- 
sured before ischemia and 30 minutes after reperfusion. 
Myocardial oxygen consumption (MVOz) was measured 
before ischemia nd 5, 15, 20, and 30 minutes after reperfu- 
sion as described previously. 1'2'3'9 Arterial and venous 
blood was collected with the heart in the beating nonworking 
state. The hemoglobin concentration and the oxygen satura- 
tion were measured with a blood gas analyzer (Stat Profile 5, 
NOVA Biomedical, Waltham, Mass.) and corrected for 
temperature and pH. MVO 2 was calculated by these values 
as the following equation: 
MVO2 (ml/min per 100 gm tissue) 
= (Arterial 02 content - Coronary sinus 02 content) 
• CBF/rnyocardial wet weight 
02 content (ml/dl) 
= 1.39 • Hb • 02  saturation/100 + 0.0031 • Po2 
where CBF is coronary blood flow, Hb is hemoglobin, and 
Po 2 is oxygen tension. 
Circulating white blood cell counts were measured with 
an automated counter (Technicon H- l ,  Miles Laborato- 
ries, Tarrytown, N.Y.). 
Experimental protocol. Baseline measurements were 
made after a 20-minute quilibrium period. Then both the 
perfusate and water bath were cooled to 15 ~ C. At  10 
minutes after the start of cooling, when the myocardial 
temperature reached 15 ~ C, the heart was subjected to 
cold cardioplegic ischemic arrest by infusion of 20 ml/kg 
body" weight of cardioplegic solution over 2 minutes 
followed by topical cooling (myocardial temperature was 
maintained at 10 ~ C). A second dose of cardioplegic 
solution (10 ml/kg) was given after 60 minutes. The 
composition of cardioplegic solution was 0.45% sodium 
chloride and 2.5% dextrose solution with a 20 mEq/L 
concentration of potassium chloride and a 6 mEq/L 
concentration of sodium bicarbonate (pH 7.4 a t  37 ~ C, 
osmolarity 360 mOsm/L). Reperfusion was begun with the 
perfusate at room temperature (25 ~ C) and then rewarm- 
ing to normothermia was carried out over 25 minutes. 
Mean coronary perfusion pressure was maintained at 20 
mm Hg during the first 5 minutes, raised to 40 mm Hg 
during the second 5 minutes, and then kept at 60 mm Hg 
until the end of the experiment. During the cooling period 
and the first 15 minutes of reperfusion, the oxygenator was 
bubbled with a high concentration of oxygen (95% oxygen 
and 5% carbon dioxide) to imitate the arterial blood gas 
conditions as clinical cases. Thereafter the gas was 
changed to 20% oxygen, 5% carbon dioxide, and 75% 
nitrogen. 
Experimental groups. The hearts were divided into 
four groups: In the control group (n = 8), blood alone was 
reperfused without intervention. In group L-arginine (n = 
8), L-arginine was infused into the side port of the arterial 
cannula during the first 20 minutes of reperfusion at a rate 
calculated to achieve a concentration of 3 mmol/L 9 in the 
coronary blood. In group leukocyte depletion (n = 8), the 
hearts were reperfused with blood depleted of leukocyte 
by passing all of the blood in the apparatus through a 
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Table II. Percent recovery of ventricular function 
Group, 
Control L-ARG LD L-ARG + LD 
DP(max) 75.5 -+ 8.0 94.5 -+ 3.4*? 83 +- 6.9* 95.4 + 4.5*? 
DP(V10) 75.1 § 8.0 90.3 _+ 5.3* 86.9 _+ 8.4* 92.8 _+ 5.2* 
dP/dt(max) 68.3 -+ 8.8 88.8 - 3.8*? 79.3 - 8.1" 100.6 _+ 8.7"?:~ 
dP/dt(V10) 66.8 +- 11.2 87.5 _+ 4.9* 85.2 _ 9.7* 101.1 + 11.4'?:~ 
-dP/dt(max) 60.7 _+ 6.8 74.1 -+ 9.5* 69.4 + 6.9 88.8 + 10.9"?~: 
DP(max), Maximum peak developed pressure; DP(VIO), peak developed pressure at a constant balloon volume (V10); dP/dt(max), maximum of peak positive 
LV dP/dt; dP/dt(VlO), LV dP/dt at V10; VIO, volume to produce an end-diastolic pressur e of 10 mm Hg during preischemic period; -dP/dt(max); maximum 
of peak negative LV dP/dt; L-ARG, L-arginine; LD, leukocyte depletion. Data are mean • standard eviation. Values are percent of baseline. 
*p < 0.05 versus the control group. 
"~p < 0.05 versus group LD. 
:~p < 0.05 versus group L-ARG. 
Table III. Percent recovery of coronary blood flow 
Group 
Control L-AR G LD c-AR G + LD 
Reperfusion, min 
5 21.3 + 14.8 38.4 _+ 32.8 23.1 + 9.5 36.3 _+ 15.5 
10 67.4 _+ 28.3 110.1 • 48.4 73.0 _+ 28.8 113.9 + 33.3 
15 113.6 +_ 29.2 201.2 _+ 28.0"? 114.2 _+ 25.8 197.0 _+ 47.2*? 
20 119.4 _+ 34.4 212.2 _+ 38.4*? 126.4 +_ 23.0 204.2 _+ 43.1"? 
25 122.2 _+ 34.5 209.4 _+ 42.2*? 135.3 + 24.0 204.5 • 32.2*? 
30 133.0 _+ 31.6 203.2 _+ 32.1"? 156.3 _+ 29.0 222.0 _+ 30.4*? 
Data are mean -+ standard eviation. L-ARG, L-Arginine; LD, leukocyte depletion. 
*p < 0.05 versus the control group. 
tp < 0.05 versus group LD. 
white blood cell removal filter (Sepacell R-500A, Asahi 
Medical Co., Tokyo, Japan) while the hearts were ar- 
rested. In group I.-arginine+leukocyte depletion (n = 8), 
the hearts were reperfused with leukocyte-deplete d blood 
and L-arginine was infused as in group L-arginine. 
All animals in this study received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy 
of Sciences and published by the National Institutes of 
Health (NIH Publication No. 80-23, revised i978). 
Statistics. All values were expressed as mean +_ standard 
deviation and analyzed by a statistical nalysis system (SPSS, 
SPSS Inc., Chicago, Ill.). The one-way analysis of variance 
and repeated-measures two-way analysis of variance were 
used to compare the differences in recovery between groups. 
Data were further compared by the Student-Newman-Keuls 
test if analysis of variance was significant. Ap value less than 
0.05 was considered to be significant. 
Results 
Baseline measurement. There were no significant 
differences among the four groups in baseline data. 
(Table I). 
White blood cell counts. White blood cell counts 
before ischemia were similar in the four groups: 
group L-arginine (3161 _ 755/mm3), group 
L-arginine+leukocyte depletion (3584 + 875/mm3), 
group leukocyte depletion (3765 +- 940/mm3), and 
the control group (3126 _+ 593/mm3). Leukocyte 
depletion effectively removed more than 97% of 
the leukocytes before reperfusion. In groups 
L-arginine+leukocyte d pletion and leukocyte de- 
pletion, white blood cell counts decreased to 69 _+ 
40/mm 3 and 83 ___ 52/mm 3 at reperfusion, respec- 
tively. In group L-arginine and the control group, 
white blood cell counts at reperfusion were 86% to 
87% of preischemic levels: group L-arginine (2721 _+ 
639/mm3), control group (2943 _+ 593/mm3). 
LV function (Table II). Groups L-arginine, 
L-arginine+leukocyte depletion, and leukocyte de- 
pletion achieved significantly greater ecovery of all 
systolic function indices than the control group, 
including maximum developed pressure, positive 
maximum dP/dt, developed pressure at V10, and 
dP/dt at V10 at 30 minutes of reperfusion. Group 
L-arginine +leukocyte depletion also showed greater 
improvement in the recovery of maximum dP/dt and 
dP/dt at V10 than groups L-arginine and leukocyte 
depletion. Group L-arginine also showed better re- 
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Table IV. Percent recovery of MVO 2 
Group 
Control L-ARG LD L-AR G + L D 
Reperfusion, min 
5 44.5 _+ 29.4 46.6 • 24.7 40:9 • 23.7 48.9 + 15.7 
15 85.0 _+ 26.5 104.2 • 30.3 115.5• 35.4 125.4 • 33.5 
20 87.6 + 15.3 111.8 • 27.1 98.4 • 26.3 132.5 • 46.8* 
30 76,1 • 22.1 96.8 • 17.6 94.4 • 12.9 110.1 • 19.2" 
Data are mean -+ standard eviation. L-ARG, L-Arginine; LD, leukocyte depletion. 
*p < 0.05 versus the control ~rouo. 
covery of maximum developed pressure and maxi- 
mum dP/dt than group leukocyte depletion. The 
effects on recovery of diastolic function were great- 
est in group L-arginine+leukocyte depletion, which 
had greater ecovery of maximum negative dP/dt 
than the other three groups. Group L-arginine also 
showed better ecovery than the control group. 
Coronary blood flow (Table III). Groups 
L-arginine+leukocyte d pletion and L-arginine had 
significantly higher coronary blood ttov~ than group 
leukocyte depletion and the control group, with 
flows reaching over 200% of baseline values. Group 
leukocyte depletion had higher postischemic coro- 
nary blood flow than the control group, but this 
difference was not statistically significant. 
MVO 2 (Table IV). At 20 and30 minutes of 
reperfusion, group L-arginine+leukocyte d pletion 
showed significantly higher recovery of MVO2 than 
the control group. Groups L-arginine and leukocyte 
depletion demonstrated higher MVO 2 than the con- 
trol group at 15, 20, and 30 minutes of reperfusion, 
but these differences were not statistically significant. 
Coronary endothelial function (coronary vascular 
resistance response) (Table V). Recovery of the 
coronary vascular esistance response to the infu- 
sion of acetylcholine at 30 minutes of reperfusion 
was significantly better in groups L-arginine, L- 
arginine+leukocyte depletion, and leukocyte deple- 
tion than in the control group. However, all four 
groups showed the same degree of recovery of 
coronary vascular esistance response for trinitro- 
glycerin infusion at 30 minutes of reperfusi0n. 
Discussion 
These results demonstrate hat either L-arginine 
administration or leukocyte depletion during reper- 
fusion improved recovery of both systolic and dia- 
stolic ventricular function and endothelial function 
in neonatal lamb hearts after hypothermic ar- 
dioplegic ischemia. Moreover, L-arginine infusion 
combined with leukocyte depletion during reperfu- 
sion resulted in greater recovery of mechanical 
function and coronary blood flow than leukocyte 
depletion alone. This combination resulted in 
greater MVO 2 than in the control group. 
Recent investigations have characterized endo- 
thelium-derived relaxing factor as NO. 12' a3 In the 
vascular system, NO release from endothelial cells 
accounts for vasorelaxation 6' 7 in vessels, as well as 
inhibition of platelet 14 and neutrophil aggregation, s 
Moreover, NO is a primary radical species and is 
inactivated by superoxide radicalsa5'16; but, con- 
versely, NO may also neutralize superoxide radi- 
cals.17 NO is produced from the semiessential amino 
acid L-arginine as it is converted to L-citrulline by 
NO synthase in endothelial cells. 4' 5 Because isch- 
emia/reperfusion results in diminished NO release 
from endothelial cells, as attempts have been made 
to supplement the reduced NO to attenuate myo- 
cardial injury associated with ischemia/reperfusion 
injury. In normothermic schemic models in cats or 
dogs, the administration of NO donors, a9 NO it- 
self, 2~ or a precursor of NO L-arginine TM 22 has been 
reported to ameliorate reperfusion i jury. We 9 have 
previously demonstrated that infusion of L-arginine 
at 3 mmol/L during the early phase of reperfusion 
significantly improved endothelial dysfunction and 
functional recovery of the LV after hypothermic 
ischemia/reperfusion n eonatal lamb hearts. 
The exact mechanisms by which L-arginine is 
beneficial remain unclear, but if NO release is 
maintained close to the site of injury, it could have 
cytoprotective effects by inhibiting neutrophil aggre- 
gation and adherence. Recently, NO has been 
shown to be an endogenous inhibitor of leukocyte 
chemotaxis9 adherence, 24and activation. 25 Normal 
endothelial ceils release NO basally, and this NO 
may prevent leukocytes from adhering to endothe- 
lial cells. In contrast, decreased basal release of NO 
after myocardial ischemia/reperfusion will favor ad- 
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Table V. Percent recovery of coronary endothelial function 
Group 
Control L-ARG LD L-ARG + LD 
CVVR recovery to ACh (10 -7 tool/L) 39.2 _+ 13.9 61.0 +- 14.8" 57.9 -+ 13.3" 53.5 -+ 14.1 
CVVR recovery to TNG (3 • 10 -5 mol/L) 42.4 _+ 15.6 36.4 _+ 15.4 36.5 +11.5 37.7 + 10.2 
Data are mean -+ standard eviation. CVVR, Coronary vascular esistance response; ACh, acetylcholine; TNG, trinitroglycerin; L-ARG, L-arginine; LD, 
leukocyte depletion. 
*p < 0.05 versus the control group. 
herence of leukocytes to the coronary endothelium, 
which is likely involved in leukocyte-induced myo- 
cardial injury. 26 In a report by Kubes, Suzuki, and 
Granger, 24 inhibition of basal release of NO with 
N-nitro-I~-arginine methyl ester (L-NAME) in- 
creased neutrophil adherence to postcapillary venu- 
lar endothelium by fifteenfold. This increased neu- 
trophil adherence was completely reversed with 
exogenous i~,arginine, suggesting that endothelium- 
derived NO is an important intrinsic modulator of 
leukocyte adherence. 24However, the present study 
showed that the combination of L-arginine with 
leukocyte depletion during reperfusion resulted in 
the highest coronary blood flow and MVO 2 and 
functional recovery, which indicated that L-arginine 
appeared to have beneficial effects beyond leukocyte 
inhibitory effect o prevent "vascular stunning. ''27 
Another possible mechanism of the cardioprotec- 
tire effect of L-arginine is through direct coronary 
vasodilation.6, 7 Our laboratory found that nitroglyc- ' 
erin administration would offset the deleterious 
effects of high-pressure reperfusion. 2s We 29 also 
, found that vasodilation with nitroglycerin would 
provide better recovery of mechanical function in 
the postischemic period after cold cardioplegic sch- 
emia. Increases in coronary blood flow may poten- 
tially lead to improved ventricular function through 
the Gregg or "garden hose" effect, 3~ but we 9 have 
shown that an infusion of L-arginine without isch- 
emia does not improve ventricular function. Recent 
experiments from our laboratory have: also shown 
that postischemic infusions of theophylline (which is 
an adenosine receptor antagonist) caused increased 
coronary blood flow and lowered coronary resis- 
tance, but iwas associated with worse recovery of 
ventricular function, leading us to conclude that 
coronary vasodilation alone during reperfusion is 
not sufficient to improve recovery of contractile 
function after hypothermic schemia. 3a 
Increased endothelial production of NO with 
I.-arginine infusion also may be cardioprotective 
through the action of directly quenching superoxide 
free radicals. NO is a primary radical species and is 
inactivated by superoxide radicals, 15' 16 but NO may 
also neutralize superoxide radicals. 17 Conditions 
associated with enhanced production of superoxide 
have been shown to increase neutrophil adherence. 
Thus administration of NO could prevent endothe- 
lial injury resulting from toxic substances such as 
superoxide radicals. 
Others have reported that augmentation of NO 
by I.-arginine increases postischemic njury or that 
blockade of NO synthase with an arginine analog 
decreases postischemic njury. 1~ 11 The mechanism 
by which NO expresses deleterious effects is sug- 
gested to be cytotoxic peroxynitrite and hydroxyl 
radical formation from NO. 32 However, these ob- 
served deleterious effects may be model dependent. 
Takeuchi and associates10 reported a negative ino- 
tropic effect of L-arginine in isolated rabbit hearts, 
but they used crystalloid perfusion, which may 
induce maximum vasodilation from the baseline mea- 
surement, and in that model the beneficial vasodila- 
tory effect of L-arginine will be offset after reperfusion 
compared with our blood-perfused model. Despite the 
cytotoxic effects of NO observed in the in vitro study, 
NO has other tissue-sparing effects based on antineu- 
trophil, antiplatelet, direct quenching of superoxide 
free radicals, and vasodilator actions within ischemic 
tissue. These may play much more important roles, 
especially in the in vivo environment. 
The current studies have several limitations. First, 
the model that was used is an isolated, blood- 
perfused heart system. The advantages and disad- 
vantages of this model for the assessment of cardiac 
function after ischemia have previously been dis- 
cussed. 1-3 We have continued to use this model 
because of the elimination of the influence of ad- 
renergic, neural, and anesthetic variations and the 
ability to provide coronary blood flow independent 
of mechanical function of the heart. 
Although the current experiments strongly sug- 
gest that the beneficial effects of L-arginine when 
administered after hypothermic ischemia seem to 
1 7 8 Hiramatsu et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
July 1995 
involve mechanisms beyond leukocyte inhibition, 
the precise mechanisms till remain unclear. The 
current experiments do clearly show that reperfu- 
sion with leukocyte-depleted blood and infusion of 
L-arginine at 3 mmol/L during reperfusion have 
~dditive ffects on the functional recovery of neonatal 
lamb hearts after cold cardioplegic ischemia. Thus the 
beneficial effects of L-arginine after ischemia/reperfu- 
sion seem to involve mechanisms in addition to leuko- 
cyte inhibition, most likely enhanced endothelial pro- 
duction of NO. Additional studies in the whole animal 
will help to define the potential clinical value of 
postischemic nfusion of L-arginine. 
We thank Mark A. Cioffi, MAT, for his technical 
assistance. 
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